@article{2d14223530d64e9692c3afc40943e8d6,
title = "Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies",
author = "Ahluwalia, \{Manmeet S.\} and \{de Groot\}, John and Liu, \{Wei Michael\} and Gladson, \{Candece L.\}",
note = "Glioblastoma (GBM) is an extremely aggressive, infiltrative tumor with a poor prognosis. The regulatory approval of bevacizumab for recurrent GBM has confirmed that molecularly targeted agents have potential for GBM treatment. Preclinical data showing that SRC and SRC-family kinases (SFKs) mediate intracellular signaling pathways controlling key biologic/oncogenic processes provide a strong rationale for investigating SRC/SFK inhibitors, eg, dasatinib, in GBM and clinical studies are underway.",
year = "2010",
month = dec,
day = "8",
doi = "10.1016/J.CANLET.2010.08.014",
language = "American English",
volume = "298",
journal = "Cancer Letters",
}